Guillain-Barre Syndrome

Guillain-Barre syndrome is an autoimmune, inflammatory polyneuropathy characterized by progressive ascending paralysis resulting from the demyelination of peripheral nerves. Triggered frequently by molecular mimicry following infections like *Campylobacter jejuni* or, rarely, certain vaccinations, the condition demands clinical vigilance for respiratory failure, which affects approximately one-third of patients. Diagnosis relies on identifying clinical symptoms, such as areflexia and symmetric weakness, supported by cerebrospinal fluid analysis showing elevated protein without pleocytosis. While prognosis is generally favorable, with most patients achieving independent mobility within six months, treatment focuses on high-dose intravenous immunoglobulin (IVIG) or plasma exchange to accelerate recovery. Steroids lack therapeutic efficacy in this context. Managing the condition requires careful monitoring of forced vital capacity and autonomic stability, alongside supportive care to address potential complications like deep vein thrombosis and persistent pain.